ABSTRACT
BACKGROUND: The two most common skin cancers are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The purpose of this study was to describe the detailed clinical behavior of BCC and SCC in the head and neck region over 19 years at a single institution. METHODS: A retrospective analysis was performed for all patients with non-melanoma skin cancer who had undergone surgical resection over an 18-year period. Patient charts were reviewed for demographic information, tumor size, onset-to-diagnosis, anatomic location, clinical subtype, histologic differentiation, method of surgical treatment, and recurrence. RESULTS: The review identified 265 cases of either BCC or SCC in 226 patients. Of the 226 patients, 80 (35.4%) were men and 146 (64.6%) were women. BCC (n=138, 55.9%) was more frequent than SCC (109, 44.1%). The most frequent age group was 70-to-79 year olds (45 patients, 35.2%) for BCC and 80-to-89 year olds (41 patients, 41.8%) for SCC. By aesthetic units of the face, the most common location was the nasal unit (44 cases, 31.9%) for BCC and the buccal unit (23 cases, 21.1%) for SCC. The most common clinical subtype of BCC was the nodular type (80 cases, 58.0%). Local flaps were most commonly used to cover surgical defects (136 cases, 55.1%). Recurrent rates were 2.2% for BCC and 5.5% for SCC. CONCLUSION: In our study, many characteristics of BCC and SCC were compared to previously published reports were generally similar, except the ratio of BCC to SCC. Further study can help to establish the characteristics of BCC and SCC.
Subject(s)
Female , Humans , Male , Carcinoma, Basal Cell , Carcinoma, Squamous Cell , Epithelial Cells , Head , Methods , Neck , Recurrence , Retrospective Studies , Skin NeoplasmsABSTRACT
No abstract available.
Subject(s)
Blepharoplasty , Incidental Findings , Lymphoma, B-Cell, Marginal ZoneABSTRACT
Hepatitis B virus infection is known to be associated with various types of glomerulonephritis (GN), including membranous GN, membranoproliferative GN, and mesangial proliferative GN. Although there has been considerable experiences with interferon in clinical trials during the past decade, acute renal failure as a complication of interferon treatment has rarely been reported. We report a case in which acute renal failure with proteinuria was associated with interferon-alpha treatment. A 33-year-old man with chronic hepatitis B presented with diarrhea and RUQ pain. Two weeks after INF-alpha treatment, Oliguria and proteinuria suddenly occurred, although the hepatic function was improved. With discontinuation of interferon treatment and ultrafiltration, his renal function was improved.
Subject(s)
Adult , Humans , Acute Kidney Injury , Diarrhea , Glomerulonephritis , Hepatitis B virus , Hepatitis B, Chronic , Hepatitis, Chronic , Interferon-alpha , Interferons , Oliguria , Proteinuria , UltrafiltrationABSTRACT
To examine the effectiveness and safety of erythropoietin on the anemia of end-stage chronic renal failure, we administered recombinant human erythropoietin(rHuEPO), Eporon(R), to 66 patients with anemia and chronic renal failure who were undergoing hemodialysis or peritoneal dialysis. All received Eporon(R) intravenously, two or three times per week at 150unit/kg, and then the dose of Eporon(R) was adjusted to 75-300unit/kg/week according to the hemoglobin response. The results of this study judged 19(39.6%) of 48 patients as being in a "markedly improved" condition while 23(47.9%) of 48 patients were judged as being in an "improved" condition. At results, the response rate of this study was 87.5%(42/48 patients). This was the same as the target response rate, 90%(p= 0.564). Serious adverse events occured in 6 cases during the study, but all proved to be unrelated to Eporon(R). These events included itching 1(1.5%), urticaria 1(1.5%) and headache 1(1.5%). No patients discontinued to participate in the study except one patient who withdrew from the study voluntarily. The symptoms of all adverse events eventually decreased and disappeared during the clinical study. No factors in the clinical laboratory tests changed significantly (p<0.05) except for the decrease of TSR and ferritin, a consequence of using iron hemoglobin synthesis caused by Eporon(R) administration. The significant increase in blood pressure, which could not be proved to be related to Eporon(R), disappeared during the study. Anti-Epo antibody was not detected in any samples. These results demonstrate that Eporon(R) is effective in many patients with the anemia of end-stage chronic renal failure.
Subject(s)
Humans , Anemia , Blood Pressure , Erythropoietin , Ferritins , Headache , Iron , Kidney Failure, Chronic , Peritoneal Dialysis , Pruritus , Renal Dialysis , UrticariaABSTRACT
No abstract available.
ABSTRACT
No abstract available.